Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
General Internal Medicine
Would you ever omit adjuvant therapy for rectal cancer in patients who underwent primary resection (TME), without any neoadjuvant therapy?
What about T3N0 disease? Would you use a recurrence score to help inform decisions?
Related Questions
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Would you change treatment approach for rectal cancer with an associated intussusception?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Which PD-1 inhibitor will you use with chemotherapy in initial treatment of patients with metastatic anal cancer?
Would you offer zolbetuximab in a non-Asian population?
When screening for malignancy, do you order CT with contrast (or) both with and without contrast?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
How are you sequencing immunotherapy with zolbetuximab in locally advanced/metastatic GEJ cancer when CPS >5 and Claudin 18.2+ (>75%)?
Would you consider using enasidenib off-label for a cholangiocarcinoma with IDH2 mutation that has progressed on numerous lines of standard of therapy?
Will you offer durva-FLOT perioperatively for adenocarcinoma of the esophagus with PDL1<1?